摘要
目的:评价噻托溴胺对稳定期慢性阻塞性肺病(COPD)患者运动耐力的影响,探讨其可能的机制。方法:将60例稳定期COPD患者随机分成试验组(A组),噻托溴胺粉雾剂吸入;对照组(B组),空白安慰剂吸入。于研究第1、43、85天检查呼吸困难的评分、6 min行走距离(6MWD)、1 s用力呼气量(FEV1)占预计值的比值(FEV1%)和深吸气量(IC)等指标。结果:试验组用药后6、12周呼吸困难评分的下降值较对照组比较有显著差异(z=4.433、4.026,均为P<0.001);6MWD试验组用药后6、12周较对照组有显著提高(t=3.004、4.594,均P<0.01);试验组用药后FEV1%和FEV1/用力呼气量(FVC)虽有所改善,但和对照组比较均无显著差异(均P>0.05),其中FEV1%的改善要好于FEV1/FVC改善,但是亦无统计学差异;试验组用药后6、12周IC较对照组比较有显著增大(t=3.204、3.109,均P<0.01)。结论:噻托溴胺作为一种新型长效抗胆碱类药物,通过增加IC,减少肺的残气容量,临床上可以明显提高COPD患者的运动耐力,改善患者的生活质量。
Objective To investigate the effects of tiotropium on the exercise endurance of patients with stable chronic obstructive pulmonary disease（COPD） and its possible mechanisms. Methods 60 stable COPD cases were randomly allocated into the trial group（ tiotropium inhaling） ,as group A,and control group（ placebo inhaling） as group B. Dyspneic respiration was scored on day 1,43 and 85,6 minute-walk-distance （6MWD）, FEV1% and inspiratory capacity （IC） were measured respectively. Results The level of dyspneic respiration was significantly decreased in group A after receiving tiotropium 6 weeks （z =4. 433 ,P =0. 000） and 12 weeks （z =4. 026,P =0.000 1 ）. The 6MWD was significantly increased in group A after receiving tiotropium 6 weeks （ t = 3. 004, P = 0. 004） or 12 weeks （t = 4. 594, P = 0. 000）. The FEV1% and FEV1/FVC were improved in group A,ahhough there was no significant difference comparing to group B （P 〉0.05 for all comparisons）,and the improved level in FEV1 % was greater than FEV1/FVC. IC was increased significantly after 6 weeks （t =3. 204,P =0. 002） and 12 weeks （t =3. 109,P =0.003）. Conclusion Tiotroplum, as a new long-acting anticholinergic bronchodilator, has the function to increase IC, decrease residual capacity,and improve the exercise endurance in patients with stable COPD,thus,improve the life quality in these patients.
出处
《东南大学学报（医学版）》
CAS
2007年第5期332-335,共4页
Journal of Southeast University(Medical Science Edition)
关键词
噻托溴胺
肺疾病
慢性阻塞性
运动耐力
tiotropium
pulmonary disease,chronic obstructive
exercise endurance
